Requires health insurance coverage for histotripsy procedures (EN NO IMPACT See Note)
Summary
HB 622 creates a new advisory board within the Louisiana Department of Insurance to review and make medical recommendations on approving new treatments for rare cancers. The board is made up of state health and insurance officials, representatives from cancer research and treatment institutions, health plans, managed care, and two oncologists who specialize in rare cancers. The board is tasked with holding quarterly public meetings, compiling a written report after each meeting, and submitting those reports to the Legislature.
The bill also authorizes the commissioner of insurance to adopt administrative rules needed to implement the new advisory process. Although the bill caption in the context refers to health insurance coverage for histotripsy procedures, the enrolled text itself focuses on rare cancer treatment review and advisory-board procedures rather than setting a direct coverage mandate. As enacted, it adds a new section to Title 22 governing insurance-related oversight of rare cancer treatments and creates a formal consultative process for evaluating emerging therapies.
Impact
HB 622 enacts R.S. 22:1076.1, adding a new advisory board structure within the Department of Insurance and requiring regular reporting to the Legislature. It affects the Department of Insurance, the Louisiana Department of Health, Medicaid, cancer research institutions, health plans, managed care organizations, and oncology specialists by placing them in a formal review role for rare cancer treatments. The bill does not itself appear to mandate coverage terms in the enrolled text, but it establishes a mechanism that could influence future insurance policy and treatment approval decisions through administrative rulemaking and legislative reporting.
Sentiment
The bill appears to have broad bipartisan support and little visible opposition. It passed the House 98-1, the Senate 38-0, and the House concurrence vote 91-0, indicating strong consensus in favor of the measure. The available record contains no committee transcript debate, so the overall sentiment can be inferred primarily from the overwhelming vote margins and the absence of recorded controversy.
Contention
The main point of potential contention is the bill’s relationship between insurance regulation and medical decision-making: it places an insurance department commissioner in a process that reviews rare-cancer treatments, while also involving health agencies, insurers, and cancer specialists. Another possible issue is whether the advisory board’s recommendations could indirectly affect coverage decisions or access to experimental or high-cost therapies, even though the enrolled text does not expressly require coverage. No specific objections are documented in the provided materials, and the recorded votes suggest any concerns were not significant enough to prevent near-unanimous passage.